Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD
Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.
Postpandemic Breast Cancer Screening Rates Explained: Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
